OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Amgen

Protocol Number
20110265

To Learn More Call
201-510-0910

RANDOMIZED PHASE II STUDY OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091401

To Learn More Call
201-510-0910

A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Alliance

Protocol Number
A091304

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910

S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1320

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6134

To Learn More Call
201-510-0910

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack